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Received October 16, 2013; accepted March 18, 2014AbstractBackground: The ubiquitin ligase Cbl-b potently modulates T lymphocyte immune responses and is critical in modulating tumor-induced
immunosuppression. The influence of Cbl-b in modulating T lymphocyte activity against prostate cancer remains ill defined. We have deter-
mined the effects of silencing Cbl-b expression in T lymphocytes and their subsequent cytotoxic activity against prostate cancer cells.
Methods: T lymphocytes were isolated from the spleens of C57BL/6 mice. Lipofectamine-directed transfection of T lymphocytes with specific
small interfering RNA (siRNA) silenced Cbl-b expression, which was confirmed by Western immunoblotting. The siRNA species were chosen
that promoted the greatest transfection efficiency and dampened Cbl-b expression in T lymphocytes. The expression of CD69, CD25, and CD71
by the transfected T lymphocytes was determined by flow cytometry. T lymphocyte proliferation was assessed by CCK-8 assay. Enzyme-linked
immunosorbent assay (ELISA) was used to measure the secretion of interleukin (IL)-2, interferon (IFN)-g, and tumor necrosis factor (TNF)-b.
The objective was to compare the cytotoxic activity of transfected T lymphocytes and nontransfected (i.e., negative control) T lymphocytes
against the murine prostate cancer cell line target RM-1 in vitro.
Results: We selected a specific siRNA that decreased T lymphocyte Cbl-b expression to 15%. The siRNA-transfected T lymphocytes showed
higher proliferation; higher CD69, CD25, and CD71 expression ( p < 0.001); and higher IL-2, IFN-g, and TNF-b secretion ( p < 0.05), compared
to the nontransfected cells. Transfected T lymphocytes were also more potent at killing RM-1 prostate cancer cells, compared to the negative
control in vitro.
Conclusion: Silencing Cbl-b significantly enhanced T lymphocyte function and T lymphocyte cytotoxicity activity against a model prostate
cancer cell line in vitro. This study suggests a potentially novel immunotherapeutic strategy against prostate cancer.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Prostate cancer is the second most prevalent cancer in men
and accounts for approximately 14% of all male cancers
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Asspredominantly achieved with hormone therapy. However, most
patients over time develop metastatic disease, despite
androgen ablation. This state is referred to as castration-
resistant prostate cancer.2 Patients presenting with castration-
resistant prostate cancer have limited treatment options
available to them, and a poor prognosis.
Evidence has shown that a defective immune response may
be present in the setting of prostate cancer. Despite the pres-
ence of immunological effector T cells, which recognize
tumor-associated antigens in prostate tissue, T cells are
actively tolerant to the tumor, and become incapable ofociation. All rights reserved.
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microenvironment is highly immunosuppressive, which is
closely associated with the augmented expression of trans-
forming growth factor (TGF)-b and the presence of CD4þ
regulatory T cells.4,5 A key question is how to effectively
activate tumor-specific and cell-mediated immunity in adopt-
ing immunotherapeutic targeting of prostate cancer. Several
Phase I/II clinical trials have demonstrated that treating in-
dividuals with dendritic cell-based immunotherapeutic vac-
cines can effectively activate T cell-mediated immunity, which
results in greatly improved median overall survival rates and a
relative reduction in the risk of death, compared to treating
individuals with a placebo.6e8 Thus, strengthening the anti-
tumor immune response, especially by enhancing T cell acti-
vation, provides a promising immunotherapeutic approach for
targeting prostate cancer.
The first E3 ligase to be identified as a major participant in
cell-mediated immunity was Cb1-b, whose key function is to
ensure a delicate balance between T cell activation, immu-
nological tolerance, and autoimmunity in vivo.9 When total
Cbl-b is ablated, T cells exhibit a hyperactivated state, a pre-
dilection to spontaneous autoimmunity, and markedly
increased secretion of interleukin (IL)-2, IL-17, and interferon
gamma (IFN-g). The total ablation of Cb1-b moreover pro-
motes spontaneous tumor rejection in gene knockout mouse
models in vivo. This has been demonstrated in cancers such as
leukemia,10 skin cancer,11 TC1 tumor cells,12 and lym-
phoma.13 However, to the best of our knowledge, we have not
seen any reports in the context of Cb1-b and prostate cancer.
Furthermore, small interfering RNAs (siRNAs) hold great
promise as a reversible therapeutic tool, compared to gene
knockout approaches. Bearing that in mind, we used sequence-
specific siRNA to silence the expression of Cbl-b and studied
changes in the immunoreactivity of splenic T cells in a mouse
model. We also assessed the immunological and tumoricidal
activity of the transfected T cells against the prostate cancer
cell line RM-1 in vitro.
2. Methods2.1. Reagents and antibodiesAnti-CD3-FITC (clone 145-2C11), anti-CD69-PE (clone
H1.2F3), anti-CD25- Percp-cy5.5 (clone PC61), anti-CD71-
FITC (clone C2F2), and mouse T lymphocyte enrichment
set-DM were all obtained from BD Biosciences Pharmingen
(San Diego, CA, USA). Antimouse CD3 functional antibody
(clone 17A2) was purchased from eBioscience (San Diego,
CA, USA). The cell counting kit-8 and the total protein
extraction kit were both obtained from KeyGen Biotech
(Nanjing, China). The Lowry protein assay kit was obtained
from Sangon Biotech (Shanghai, China). The antibody tar-
geted against Cbl-b was obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Concanavalin A (Con A) and
peroxidase-conjugated rabbit antimouse immunoglobulin G
were obtained from Sigma (Saint Louis, MS, USA). Lip-
ofectamine 2000 was obtained from Invitrogen (Carlsbad, CA,USA). Roswell Park Memorial Institute Medium (RPMI) 1640
culture medium, Opti-MEM medium, and fetal calf serum
(FCS) were all obtained from Gibco (Grand Island, NY, USA).
Cytokine-detecting enzyme-linked immunosorbent assay
(ELISA) kits were obtained from Wuhan Boster Biological
Technology (Hubei, China). The cytokines used were IL-2,
IFN-g, and tumor necrosis factor (TNF)-b.2.2. Mice and prostate cancer cell lineMale C57BL/6 mice were obtained from the Chinese Acad-
emy of Sciences (Shanghai, China) and were maintained under
specific pathogen-free conditions. All experiments were per-
formed in accordance with protocols approved by the Institu-
tional Animal Care and Use Committee (Tongji University,
Shanghai, China). Mice were sacrificed at age 6e8-weeks-old.
The mouse prostate cancer cell line (RM-1) was obtained from
Shanghai Cellular Institute of The China Scientific Academy
(Shanghai, China) and maintained in RPMI 1640 culture me-
dium supplemented with heat-inactivated FCS (10%), penicillin
(100 U/mL), and streptomycin sulfate (100 mg/mL). The RM-1
cell line was cultured at 37C in 5% carbon dioxide (CO2) and
in a fully humidified incubator. The Cbl-b siRNA and control
siRNAwere obtained from GeneChem (Shanghai, China). The
sequence of the Cbl-b siRNA was 5'-UGAGAUGCCCUG
AUAUUAAtt- 3' (sense strand) and5'-UUAAUAUCAGGGCAU
CUCAtt-3'' (antisense strand).2.3. T lymphocytes enrichment and identificationBD IMag Mouse T Lymphocyte Enrichment microbeads
(BD Biosciences) were used for the negative selection of T
lymphocytes from male C57BL/6 mice spleen. In accordance
with the manufacturer's protocol, we isolated 1e2  106 T
lymphocytes for each mouse spleen. The T lymphocytes were
maintained in RPMI 1640 medium supplemented with 10%
heat-inactivated FCS, and 5 mg/mL Con A. The T cells were
stained with fluorescein isothiocyanate (FITC)-conjugated
antimouse CD3e mAb and detected by flow cytometry. The T
cell purity was >95.9%. The T lymphocytes were cultured at
37C in 5% CO2 within a fully humidified incubator.2.4. Transfection of T lymphocytesThe T cells were cultured to 80e90% confluence at the
time of transfection. Single cell suspensions were prepared at a
density of 2.0  105/mL and seeded to 24-well plates in a
volume of 400 mL/well. The transfections were performed in
accordance with the manufacturer's instructions. In brief, 2 mL
of Lipofectamine 2000 (Invitrogen) and 6 mL of sequence-
specific siRNA were added into 20 mL of opti-MEM (Gibco)
reduced serum medium, mixed gently, and incubated for 5
minutes at room temperature. The diluted siRNA was com-
bined with the diluted Lipofectamine 2000 (Invitrogen) and
incubated for 20 minutes at room temperature. The siRNA-
Lipofectamine 2000 complexes were added to each well
containing the cells and the culture medium; 60 mL of mouse
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wherein the final concentration of the mouse CD3 functional
antibody was 1 mg/mL. After an incubation period of 6 hours
at 37C, 80 mL of FCS was added to each well. T cells that had
been transfected with scrambled siRNA served as the negative
control. The transfection efficiency was measured by flow
cytometry using fluorescent-labeled siRNA (NC-FAM) using
the exact same methods as described previously.2.5. Western immunoblot detection of Cbl-b protein
expressionAt 48 hours after transfecting the T cells, Cbl-b proteins
were extracted using the total protein extraction kit in accor-
dance with the manufacturer's protocol. Protein concentrations
were determined by the Lowry method. Total proteins
(30e50 mg) were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to nitrocellulose membranes. The membranes were
blocked with 1% bovine serum albumin in Tris-buffered saline
Tween-20 (TBST) at room temperature for 1 hour, and then
incubated overnight with the indicated primary antibodies (at
1:1000 dilution) at 4C. After washing with TBST, the
membranes were incubated with the appropriate horseradish
peroxidase-conjugated secondary antibodies (at 1:1500 dilu-
tion) for 45 minutes at room temperature. Visualization of the
antibody-bound protein bands was achieved by using an
enhanced chemiluminesence reagent. The protein bands were
quantified by the computerized imaging program Quantity
One (Bio-Rad, CA, USA). Data were normalized to the
reference bands corresponding to the housekeeping protein
b-actin.2.6. Flow cytometric assay of CD69, CD25, and CD71
expressionThe cell surface expressions of CD69, CD25, and CD71
were assessed after culturing for 12 hours, 24 hours, and 48
hours. All cells were washed twice in phosphate-buffered sa-
line buffer, after which the cells were stained with a combi-
nation of anti-PE-CD69, anti-Percp-cy5.5-CD25, or anti-
CD71-FITC for 30 minutes at room temperature in the dark.
The cells were washed twice in phosphate-buffered saline
buffer and samples were evaluated by flow cytometry. Data
were analyzed using the CellQuest software program (Becton
Dickinson and Company, San Jose, CA, USA).2.7. ELISA assay of cytokine secretionMouse T cells at a density of 2  105 cells/mL were seeded
into 24-well microplates and cultured in the presence of mouse
CD3 functional antibody (1 mg/mL). After 48 hours, the su-
pernatants were collected and centrifuged to remove the
transfected cells. In accordance with the manufacturer's in-
structions, transfected T cell culture supernatants were
measured by ELISA for the secretion of IL-2, INF-g, and
TNF-b.2.8. Assay of T lymphocyte proliferationCell proliferation was measured by the CCK-8 assay. After 48
hours, the transfected T cell suspensions were transferred to a 96-
well orificeplate as100-mLcell suspensionsTenmicroliters of the
CCK-8 reagent were then added to each well at a volume ratio of
10:1. The plated cells were incubated for another 4 hours at 37C
in a 5% CO2 and fully humidified cell culture incubator. The
absorbancewasmeasured for eachwell at awavelength of450nm
using a microplate reader (Bio-Rad Model 3550; Bio-Rad).2.9. Assay of the killing activity of transfected T
lymphocytes against RM-1 cellsThe killing activity of transfected T cells against the RM-1
prostate cancer target cells was measured as previously
described.14 The RM-1 cells were cultured in 96-well microtiter
plates at a density of 1 104 cells/well and in a total volume of
100 mL. Transfected T cells prepared as described previously,
and T cells that were transfected with scrambled siRNA (i.e.,
negative control) were used as the effector (E) cells. Effector T
cells were added at a density of 80  105 cells/well, 40  105
cells/well, 20 105 cells/well, and 10 105 cells/well to give a
corresponding E/T ratio of 80:1, 40:1, 20:1, and 10:1, respec-
tively. The plates were then incubated for 48 hours at 37C in a
5% CO2 and fully humidified incubator and subjected to the
CCK-8 assay. The killing activity was calculated according to
the following equation:
Killing activityð%Þ ¼ ½ðODEþODTÞ ODEþT=ODT
 100%
in which ODT is the optical density value of the target cell
controls, ODE þ T is the optical density value of the test
samples, and ODE is the optical density value of the effectors
cell controls.2.10. Statistical analysisThe data were expressed as the mean ± standard deviation
(SD). The figures show the mean ± standard error of the mean
(SEM). The differences between the groups were determined
by the Student t test. An alpha value of p < 0.05 was
considered statistically significant. Statistical analysis was
performed using SPSS analysis software (IBM, NY, USA).
3. Results3.1. The determination of T lymphocyte transfection
efficiency and Cbl-b protein expressionAfter 6 hours of transfection, the efficiency of T cell trans-
fection was determined by flow cytometry. The transfection ef-
ficiency of the T cells remained relatively stable, and the highest
transfection efficiency was 87.13% (Fig. 1A). Green fluores-
cence was observed by fluorescence microscopy of T cells
transfected with fluorescein amidite (FAM)-siRNA (Fig. 1B).
Fig. 1. (A) Graph of the efficiency of Cbl-b siRNA-transfected T cells showing that the transfection rate of FAM-siRNA-transfected T cells is 87.13%. Other data
are not shown. However, the control cells not transfected with FAM-siRNA is only 1.75%. (B) T cells analyzed under fluorescence microscope 6 hours after
transfection (100 objective lens). Most T cells emit fluorescence. (C) The expression of Cbl-b protein in the Cbl-b siRNA group, the negative control group, and
the blank group, as determined by Western immunoblot analysis. All aforementioned experiments were repeated three times and the results are very similar.
FAM ¼ fluorescein amidite; NC ¼ negative control; siRNA ¼ small interfering RNA.
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at a wavelength of 480 nm.With a fluorescence pattern scattered
in the cytoplasm, FAM green fluorescence was only observed in
successfully transfected T cells. After 48 hours of transfection,
Western immunoblot analysis of Cbl-b protein expression was
determined (Fig. 1C) and compared to the negative control and
the blank groups. The expression of Cbl-b protein in the trans-
fected T cell group was significantly lower.3.2. Silencing the Cbl-b gene promotes cell surface
expression of CD69, CD25, and CD71The cell surface expression of CD69, CD25, and CD71 were
assessed by flow cytometric analysis 12 hours, 24 hours, and 48
hours after the cells had been transfected. The mean percent
expression for CD69 was significantly higher in the transfectedgroup (68.44 ± 5.89%) than in the negative control group
(24.29± 2.06%) or the blank group (26.91± 2.77%; p< 0.001).
The mean percentage value of CD25 was significantly higher in
the transfection group (19.27 ± 1.84%) than in the negative
control group (8.18± 0.71%) or the blank group (9.25± 0.65%;
p < 0.001). The mean percentage value of CD71 was signifi-
cantly higher in the transfection group (43.26 ± 3.89%) than in
the negative control group (23.99 ± 1.97%) or the blank group
(28.09 ± 2.15%; p < 0.001). Fig. 2 shows the results.3.3. Silencing the Cbl-b gene augments the secretion of
IL-2, IFN-g, and TNF-bThe secretion of IL-2, IFN-g, and TNF-b in the T cell
supernatant was measured 48 hours after the cells were
transfected (Fig. 3). The secretion levels of IL-2 and TNF-b
Fig. 2. Cell surface expression of CD25, CD69, and CD71 on transfected T
cells, as determined by flow cytometry. The graph shows the comparative
expression of CD69, CD25, and CD71 by the transfected T cells, which is
markedly greater than the expression levels of the negative control or blank
groups (*p < 0.001). The expression values (%) are expressed as the
mean ± standard error of the mean (n ¼ 3). NC ¼ negative control; T ¼ T cell.
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comparison to either the negative control group or the blank
group ( p < 0.001). The secretion of IFN-g in the transfection
group was only marginally enhanced in the transfected T cell
group, compared to the negative control or blank control
groups ( p < 0.05).3.4. Silencing the Cbl-b gene augments T cell
proliferationAfter 48 hours of transfection, T cell proliferation was
evaluated by the CCK-8 assay (Fig. 4). The absorbance values
(A450) of the transfected T cell group, negative control group,
and blank group were 0.763 ± 0.063, 0.356 ± 0.039, and
0.383 ± 0.015, respectively. The proliferation was markedly
higher in the transfected T cell group than in the blank or
control groups ( p < 0.001).3.5. Silencing Cbl-b gene expression augments T cell
killing of RM-1 cells in vitroAt 48 hours after transfection, T cells were cocultured with
RM-1 cells in 100 mL of 1:1 mixture of RPMI 1640 culture
medium. The killing activity was analyzed by the CCK-8
assay. The killing activity of the transfected T cells (i.e., the
effectors) against RM-1 prostate cancer cells (i.e., the targets)
was higher than the killing activity in the negative control
group or blank group at each effect to target ratio (Fig. 5,
p < 0.05). The killing activity was incrementally enhanced as
the effector to target ratio increased, and reached a maximum
(62.24 ± 3.82%) at the effector to target ratio of 80:1.
4. Discussion
T cells can be specifically activated to eradicate cancer, and
thus have a critical role in antitumor immunity. The stimula-
tion of a tumor-specific T cell response has more theoretical
advantages than other forms of cancer treatment. On one hand,T cells can continue to proliferate and be activated in response
to tumor-associated immunogenic proteins expressed by a
particular cancer until all tumor cells are eradicated. By
contrast, immunological memory can be generated to kill
antigen-bearing tumor cells should they recur.15 T cell acti-
vation is a series of complex signal transduction pathways that
are initiated by molecular interactions. Cbl-b actively regu-
lates several key signaling molecules such as ZAP70, P85,
VAV, PLC-g, and PKC-q. Each of these signaling molecules
are involved in T cell activation and collectively establish the
aneroid state.16 Cbl-b knockout T cells hyperproliferate and,
interestingly, bypass the requirement for CD28 cos-
timulation.17 Furthermore, Cbl-b participates in peripheral T
cell tolerance by regulating resistance to CD4þ T regulatory
cells and TGF-b-induced immunosuppression.18 It may be that
prostate cancer is more immunogenic than previously under-
stood and is able to induce spontaneous autoantibodies in
patients.19 In addition, prostate cancer progresses relatively
slowly, which provides a sufficient period of time for the host
to generate an optimal antitumor immune response.20 There-
fore, Cbl-b may provide novel opportunities for the develop-
ment of an effective immunotherapeutic strategy to target
prostate cancer.
In the current study, we investigated whether silencing the
Cbl-b gene could effectively promote the activation and pro-
liferation of T cells using siRNA technology. We cultured cells
in vitro with an antimouse CD3 functional antibody (1 mg/mL)
that can specifically react with the mouse CD3 complex and
initiate intracellular biochemical pathways that drive cellular
activation and proliferation. However, the complete activation
of peripheral T cells is regulated by the T cell receptor com-
plex and costimulatory signals that are provided by antigen-
presenting cells such as dendritic cells.21 For example,
CD28 has an essential role in discriminating activation from
tolerance signaling.17 Only stimulation through the T cell re-
ceptor alone leads to an anergic state of naïve T cells. How-
ever, Cbl-b knockout T cells produce high levels of IL-2 and
proliferate vigorously after anti-CD3 stimulation alo-
ne.22Activated proliferating T cells express several surface
molecules, including CD25, CD69, and CD71, which are
usually poorly expressed or absent altogether on resting cells
and are thus referred to as “activation antigens”.23 A combi-
nation of flow cytometric analysis of the expression of these
markers with cell proliferation assays may improve our un-
derstanding of events leading to efficient cell-mediated im-
mune responses.24 The cell surface presence of CD69, CD25,
and CD71 are sequentially expressed after mitogenic stimu-
lation (e.g., Con A). We found that the efficiency gradually
decreased with time under the conditions of Cbl-b gene
silencing. Thus, we designed experiments to observe the
expression of CD69, CD25, and CD71 at the time points of 12
hours, 24 hours, and 48 hours. In addition, cytokines affect
proliferation, differentiation, and functional activation of T
cells that regulate cellular and humoral immune responses. By
binding to specific cell surface receptors, IL-2 drives the
proliferation of T cells, augments the cytotoxic activity of T
cells, and generates lymphokine-activated killer cells in vivo.25
Fig. 3. Changes in cytokine secretion by transfected T cells at 48 hours after transfection. The secretion of IL-2, TNF-b, and IFN-g in the T cell supernatant was
measured by ELISA. (A) The secretion of IL-2 by the transfected T cells is significantly greater than its secretion by the negative control group or blank group
(*p < 0.001). (B) The secretion of TNF-b by the transfected T cells is significantly greater than its secretion by the negative control group or blank group
(*p < 0.001). (C) The secretion of IFN-g by the transfected T cells is significantly greater than its secretion by the negative control group or blank group
(*p < 0.05). Cytokine secretion values are presented as the mean ± the standard error of the mean (n ¼ 18). ELISA ¼ enzyme-linked immunosorbent assay;
FAM ¼ fluorescein amidite; IFN ¼ interferon; IL ¼ interleukin; NC ¼ negative control; siRNA ¼ small interfering ribonucleic acid; T ¼ T cell; TNF ¼ tumor
necrosis factor.
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cells) serves many important immunopotentiating effects such
as regulating several aspects of the immune response; stimu-
lating antigen presentation through Class I and Class II major
histocompatibility complex receptors; and through its effects
on T cell proliferation and apoptosis.26 By contrast, TNF-b is
primarily secreted by T cells and promotes thymocyte prolif-
eration, activation, and differentiation, and it is widelyFig. 4. The change in proliferation of transfected T cells after 48 hours. The
proliferation rate of the transfected T cells is markedly greater than that of the
negative control group or blank group (*p < 0.001). The data are expressed as
the mean ± the standard error of the mean (n ¼ 18). NC ¼ negative control;
OD ¼ optical density; T ¼ T cell.involved in inflammation and in the immune response.27 Our
study showed that silencing the expression of the Cbl-b gene
can induce T cell proliferation (Fig. 4) and the secretion of IL-
2, IFN-g, and TNF-b (Fig. 3). Silencing the Cb1-b gene alsoFig. 5. The percent killing activity between the effector T cells and prostate
cancer cell line targets after 48 hours of coculture. T cells were cocultured
with RM-1 cells, and the killing activity determined by Cell Counting Kit-8
(KeyGen Biotech, Nanjing, China). The values are presented as the
mean ± the standard error of the mean (n ¼ 18). The killing activity of
transfected T cells against targeted RM-1 prostate cancer cells at each ratio
was higher than the activity in the negative control group or blank group
(*p < 0.05). However, there is no difference between the killing activity at the
effector:target (E:T) ratio of 40:1, compared to the ratio of 80:1 ( p ¼ 0.078).
NC ¼ negative control; T ¼ target cell.
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Thus, siRNA-mediated silencing of the Cbl-b gene promotes
the activation and proliferation of T cells in vitro.
We furthermore studied whether silencing the Cbl-b gene
could improve the cytotoxic activity of T cells against RM-1
prostate cancer cells in vitro. The RM-1 prostate cancer cell
line originated from C57BL/6 mice.28 Our data indicated that
T cells transfected with Cbl-b-specific siRNA displayed a
greater killing ability against RM-1, compared to control T
cells that were transfected with scrambled siRNA at different
E:T ratios (Fig. 5). Our observations suggested that silencing
Cbl-b by siRNA enhanced the cytotoxic activity of T cells
against RM-1 prostate cancer cells and thus provided a proof-
of-concept that this approach is indeed possible. This approach
could be a promising therapeutic option in the treatment of
prostate cancer and, interestingly, could indicate a similar role
for targeting Cbl-b in leukemia,10 skin cancer,11 TC1 tumor
cells,12 and lymphoma.13 The effect of inhibiting tumors by an
approach such as we have described in the current report
certainly requires further verification in animal models. In this
way, the mechanisms involved could be explored. Previous
studies in animal models showed that the Cbl-b knockout
mutation enhanced CD8þ T cell-mediated antitumor immu-
nity. This observation could be explained by the fact that these
cells may respond to antigenic stimulation, independent of
CD28 costimulation, and thus bypass the suppressive effect
otherwise mediated by TGF-b secreted by the tumor envi-
ronment. Whether a similar mechanism operates in vitro also
remains to be determined. We speculate that T cells trans-
fected with siRNA demonstrate enhanced cytotoxic activity
against RM-1 prostate cancer cells, partly because of CD28-
independent activation and the pattern of the secreted cyto-
kines. The killing ability of the transfected T cells interest-
ingly was not significantly different when the effector T cell to
target cell ratio was 40:1 or 80:1. We thus speculate that the
cytotoxicity activity of T cells had achieved a saturation point
when the ratio was 40:1. In conclusion, our results indicate
that silencing Cbl-b gene expression by specific siRNA can
enhance the cytotoxicity activity of T cells against RM-1
prostate cancer cells in vitro and it does so by promoting the
immune activation of T lymphocytes.
Acknowledgments
We are grateful to Huiming Mao and Ying Lu for their
expert technical assistance and for flow cytometry (FACS)
analysis.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer
2010;127:2893e917.
2. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat
Rev Immunol 2010;10:580e93.
3. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Toleriza-
tion of tumor-specific T cells despite efficient initial priming in a primary
murine model of prostate cancer. J Immunol 2007;178:1268e76.4. Zou W. Immunosuppressive networks in the tumour environment and their
therapeutic relevance. Nat Rev Cancer 2005;5:263e74.
5. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can
enhance tumorigenicity. Prostate 1997;31:61e70.
6. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S,
Kirkpatrick P, et al. Sipuleucel-T. Nat Rev Drug Discov 2010;9:513e4.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ. Sipuleucel-T
immunotherapy for castration-resistant prostate cancer. N Engl J Med
2010;363:411e22.
8. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL,
Wyand M, et al. Overall survival analysis of a phase II randomized
controlled trial of a poxviral-based PSA-targeted immunotherapy in
metastatic castration-resistant prostate cancer. J Clin Oncol
2010;28:1099e105.
9. Agdalena P, Josef MP. Cbl-b in T-cell activation. Semin Immunopathol
2010;32:137e48.
10. Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD.
Abrogating Cbl-b in effector CD8þ T cells improves the efficacy of
adoptive therapy of leukemia in mice. J Clin Invest 2010;120:3722e34.
11. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T,
et al. Spontaneous tumor rejection by Cbl-b-deficient CD8þ T cells. J Exp
Med 2007;204:879e91.
12. Paolino M, Thien CB, Gruber T, Hinterleitner R, Baier G, Langdon WY,
et al. Essential role of E3 ubiquitin ligase activity in Cbl-beregulated T
cell functions. J Immunol 2011;186:2138e47.
13. Chiang JY, Jang IK, Hodes R, Gu H. Ablation of Cbl-b provides protec-
tion against transplanted and spontaneous tumors. J Clin Invest
2007;117:1029e36.
14. Xu HS, Wu YW, Xu SF, Sun HX, Chen FY, Yao L. Antitumor and
immunomodulatory activity of polysaccharides from the roots of Actinidia
eriantha. J Ethnopharmacol 2009;125:310e7.
15. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as
cancer treatment. Lancet 2009;373:673e83.
16. Duan L, Reddi AL, Ghosh A, Dimri M, Band H. The Cbl family and other
ubiquitin ligases: destructive forces in control of antigen receptor
signaling. Immunity 2004;21:7e17.
17. Huang F, Gu H. Negative regulation of lymphocyte development and
function by the Cbl family of proteins. Immunol Rev 2008;224:229e38.
18. Wohlfert EA, Callahan MK, Clark RB. Resistance to CD4þCD25þ
regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol
2004;173:1059e65.
19. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, et al.
Autoantibody signatures in prostate cancer. N Engl J Med
2005;353:1224e35.
20. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate
cancer. Oncologist 2009;14:391e8.
21. Acuto O, Michel F. CD28-mediated costimulation: a quantitative support
for TCR signalling. Nat Rev Immunol 2003;3:939e51.
22. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al.
Cbl-b regulates the CD28 dependence of T-cell activation. Nature
2000;403:216e20.
23. Fraser JD, Strauss D, Weiss A. Signal transduction events leading to T-cell
lymphokine gene expression. Immunol Today 1993;14:357e62.
24. Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA,
Fiorentini S, et al. Flow cytometric analysis of activation markers on
stimulated T cells and their correlation with cell proliferation. Cytometry
1997;27:71e6.
25. Asano Y, Kaneda K, Hiragushi J, Tsuchida T, Higashino K. The tumor
bearing state induces augmented responses of organ-associated lympho-
cytes to high-dose interleukin-2 therapy in mice. Cancer Immunol
Immunother 1997;45:63e70.
26. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to inter-
feron-g. Annu Rev Immunol 1997;15:749e95.
27. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev
Immunol 1992;10:411e52.
28. Zhang AL, Russell PJ. Paclitaxel suppresses the growth of primary
prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice.
Cancer Lett 2006;233:185e91.
